Regeneron Pharmaceuticals (REGN) — insider trading
Health Care · NASDAQ
Regeneron Pharmaceuticals (REGN) has 102 reported SEC Form 4 insider transactions in our data, including 76 open-market sales among the most recent 100 (latest 2026-09-03).
Recent Form 4 transactions
Showing the 100 most recent of 102 recorded transactions. See all on SEC EDGAR →
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-03 | McCourt Marion | Officer (EVP Commercial) | Open-market sale | 1,131 | $857.39 | $969.7K | Form 4 |
| 2026-09-02 | Guarini Kathryn | Director | Option exercise / conversion (derivative) | 400 | — | $0 | Form 4 |
| 2026-09-02 | Guarini Kathryn | Director | Open-market sale | 400 | $850.00 | $340.0K | Form 4 |
| 2026-09-02 | Guarini Kathryn | Director | Option exercise / conversion | 400 | $719.37 | $287.7K | Form 4 |
| 2026-09-02 | McCourt Marion | Officer (EVP Commercial) | Open-market sale | 1,215 | $850.00 | $1.03M | Form 4 |
| 2026-08-19 | LAROSA JOSEPH J | Officer (EVP General Counsel and Secret) | Option exercise / conversion (derivative) | 12,282 | — | $0 | Form 4 |
| 2026-08-19 | LAROSA JOSEPH J | Officer (EVP General Counsel and Secret) | Shares withheld for taxes / exercise cost | 9,019 | $830.15 | $7.49M | Form 4 |
| 2026-08-19 | LAROSA JOSEPH J | Officer (EVP General Counsel and Secret) | Option exercise / conversion | 12,282 | $381.92 | $4.69M | Form 4 |
| 2026-08-18 | Fenimore Christopher R. | Officer (EVP Finance CFO) | Option exercise / conversion (derivative) | 6,283 | — | $0 | Form 4 |
| 2026-08-18 | Fenimore Christopher R. | Officer (EVP Finance CFO) | Shares withheld for taxes / exercise cost | 4,599 | $813.47 | $3.74M | Form 4 |
| 2026-08-18 | Fenimore Christopher R. | Officer (EVP Finance CFO) | Option exercise / conversion | 6,283 | $381.92 | $2.40M | Form 4 |
| 2026-08-10 | Zoghbi Huda Y | Director | Option exercise / conversion (derivative) | 800 | — | $0 | Form 4 |
| 2026-08-10 | Zoghbi Huda Y | Director | Open-market sale | 800 | $800.00 | $640.0K | Form 4 |
| 2026-08-10 | Zoghbi Huda Y | Director | Option exercise / conversion | 800 | $376.69 | $301.4K | Form 4 |
| 2026-08-10 | Guarini Kathryn | Director | Option exercise / conversion (derivative) | 400 | — | $0 | Form 4 |
| 2026-08-10 | Guarini Kathryn | Director | Open-market sale | 400 | $800.00 | $320.0K | Form 4 |
| 2026-08-10 | Guarini Kathryn | Director | Option exercise / conversion | 400 | $719.37 | $287.7K | Form 4 |
| 2026-07-02 | RYAN ARTHUR F | Director | Open-market sale | 200 | $650.15 | $130.0K | Form 4 |
| 2026-05-01 | RYAN ARTHUR F | Director | Open-market sale | 2 | $714.13 | $1.4K | Form 4 |
| 2026-05-01 | RYAN ARTHUR F | Director | Open-market sale | 1 | $712.09 | $712 | Form 4 |
| 2026-05-01 | RYAN ARTHUR F | Director | Open-market sale | 5 | $711.49 | $3.6K | Form 4 |
| 2026-05-01 | RYAN ARTHUR F | Director | Open-market sale | 2 | $710.87 | $1.4K | Form 4 |
| 2026-05-01 | RYAN ARTHUR F | Director | Open-market sale | 6 | $709.45 | $4.3K | Form 4 |
| 2026-05-01 | RYAN ARTHUR F | Director | Open-market sale | 4 | $707.40 | $2.8K | Form 4 |
| 2026-05-01 | RYAN ARTHUR F | Director | Open-market sale | 7 | $706.74 | $4.9K | Form 4 |
| 2026-05-01 | RYAN ARTHUR F | Director | Open-market sale | 14 | $705.56 | $9.9K | Form 4 |
| 2026-05-01 | RYAN ARTHUR F | Director | Open-market sale | 15 | $704.28 | $10.6K | Form 4 |
| 2026-05-01 | RYAN ARTHUR F | Director | Open-market sale | 24 | $703.46 | $16.9K | Form 4 |
| 2026-05-01 | RYAN ARTHUR F | Director | Open-market sale | 15 | $702.46 | $10.5K | Form 4 |
| 2026-05-01 | RYAN ARTHUR F | Director | Open-market sale | 5 | $701.76 | $3.5K | Form 4 |
| 2026-04-01 | RYAN ARTHUR F | Director | Open-market sale | 40 | $779.71 | $31.2K | Form 4 |
| 2026-04-01 | RYAN ARTHUR F | Director | Open-market sale | 4 | $778.24 | $3.1K | Form 4 |
| 2026-04-01 | RYAN ARTHUR F | Director | Open-market sale | 9 | $777.42 | $7.0K | Form 4 |
| 2026-04-01 | RYAN ARTHUR F | Director | Open-market sale | 13 | $776.62 | $10.1K | Form 4 |
| 2026-04-01 | RYAN ARTHUR F | Director | Open-market sale | 14 | $775.58 | $10.9K | Form 4 |
| 2026-04-01 | RYAN ARTHUR F | Director | Open-market sale | 8 | $774.58 | $6.2K | Form 4 |
| 2026-04-01 | RYAN ARTHUR F | Director | Open-market sale | 8 | $773.59 | $6.2K | Form 4 |
| 2026-04-01 | RYAN ARTHUR F | Director | Open-market sale | 3 | $772.76 | $2.3K | Form 4 |
| 2026-04-01 | RYAN ARTHUR F | Director | Open-market sale | 1 | $771.32 | $771 | Form 4 |
| 2026-03-02 | RYAN ARTHUR F | Director | Open-market sale | 20 | $789.28 | $15.8K | Form 4 |
| 2026-03-02 | RYAN ARTHUR F | Director | Open-market sale | 20 | $788.96 | $15.8K | Form 4 |
| 2026-03-02 | RYAN ARTHUR F | Director | Open-market sale | 2 | $787.34 | $1.6K | Form 4 |
| 2026-03-02 | RYAN ARTHUR F | Director | Open-market sale | 7 | $786.61 | $5.5K | Form 4 |
| 2026-03-02 | RYAN ARTHUR F | Director | Open-market sale | 11 | $785.48 | $8.6K | Form 4 |
| 2026-03-02 | RYAN ARTHUR F | Director | Open-market sale | 9 | $784.48 | $7.1K | Form 4 |
| 2026-03-02 | RYAN ARTHUR F | Director | Open-market sale | 10 | $783.62 | $7.8K | Form 4 |
| 2026-03-02 | RYAN ARTHUR F | Director | Open-market sale | 2 | $782.62 | $1.6K | Form 4 |
| 2026-03-02 | RYAN ARTHUR F | Director | Open-market sale | 2 | $781.21 | $1.6K | Form 4 |
| 2026-03-02 | RYAN ARTHUR F | Director | Open-market sale | 3 | $780.69 | $2.3K | Form 4 |
| 2026-03-02 | RYAN ARTHUR F | Director | Open-market sale | 5 | $779.69 | $3.9K | Form 4 |
| 2026-03-02 | RYAN ARTHUR F | Director | Open-market sale | 2 | $778.30 | $1.6K | Form 4 |
| 2026-03-02 | RYAN ARTHUR F | Director | Open-market sale | 7 | $777.46 | $5.4K | Form 4 |
| 2026-02-19 | Zoghbi Huda Y | Director | Option exercise / conversion (derivative) | 1,638 | — | $0 | Form 4 |
| 2026-02-19 | Zoghbi Huda Y | Director | Open-market sale | 4 | $790.00 | $3.2K | Form 4 |
| 2026-02-19 | Zoghbi Huda Y | Director | Open-market sale | 56 | $785.61 | $44.0K | Form 4 |
| 2026-02-19 | Zoghbi Huda Y | Director | Open-market sale | 160 | $784.45 | $125.5K | Form 4 |
| 2026-02-19 | Zoghbi Huda Y | Director | Open-market sale | 220 | $783.29 | $172.3K | Form 4 |
| 2026-02-19 | Zoghbi Huda Y | Director | Open-market sale | 298 | $782.10 | $233.1K | Form 4 |
| 2026-02-19 | Zoghbi Huda Y | Director | Open-market sale | 209 | $781.28 | $163.3K | Form 4 |
| 2026-02-19 | Zoghbi Huda Y | Director | Open-market sale | 331 | $780.45 | $258.3K | Form 4 |
| 2026-02-19 | Zoghbi Huda Y | Director | Open-market sale | 208 | $779.55 | $162.1K | Form 4 |
| 2026-02-19 | Zoghbi Huda Y | Director | Open-market sale | 53 | $778.47 | $41.3K | Form 4 |
| 2026-02-19 | Zoghbi Huda Y | Director | Open-market sale | 50 | $775.50 | $38.8K | Form 4 |
| 2026-02-19 | Zoghbi Huda Y | Director | Open-market sale | 49 | $774.68 | $38.0K | Form 4 |
| 2026-02-19 | Zoghbi Huda Y | Director | Option exercise / conversion | 1,638 | $376.69 | $617.0K | Form 4 |
| 2026-02-09 | RYAN ARTHUR F | Director | Open-market sale | 1 | $787.82 | $788 | Form 4 |
| 2026-02-09 | RYAN ARTHUR F | Director | Open-market sale | 2 | $786.29 | $1.6K | Form 4 |
| 2026-02-09 | RYAN ARTHUR F | Director | Open-market sale | 1 | $785.71 | $786 | Form 4 |
| 2026-02-09 | RYAN ARTHUR F | Director | Open-market sale | 1 | $784.59 | $785 | Form 4 |
| 2026-02-09 | RYAN ARTHUR F | Director | Open-market sale | 3 | $783.34 | $2.4K | Form 4 |
| 2026-02-09 | RYAN ARTHUR F | Director | Open-market sale | 1 | $782.53 | $783 | Form 4 |
| 2026-02-09 | RYAN ARTHUR F | Director | Open-market sale | 5 | $781.48 | $3.9K | Form 4 |
| 2026-02-09 | RYAN ARTHUR F | Director | Open-market sale | 1 | $780.09 | $780 | Form 4 |
| 2026-02-09 | RYAN ARTHUR F | Director | Open-market sale | 5 | $779.41 | $3.9K | Form 4 |
| 2026-02-09 | RYAN ARTHUR F | Director | Open-market sale | 12 | $778.53 | $9.3K | Form 4 |
| 2026-02-09 | RYAN ARTHUR F | Director | Open-market sale | 57 | $777.56 | $44.3K | Form 4 |
| 2026-02-09 | RYAN ARTHUR F | Director | Open-market sale | 10 | $776.59 | $7.8K | Form 4 |
| 2026-02-09 | RYAN ARTHUR F | Director | Open-market sale | 1 | $775.63 | $776 | Form 4 |
| 2026-02-09 | Pitofsky Jason | Officer (SVP Controller) | Option exercise / conversion (derivative) | 1,000 | — | $0 | Form 4 |
| 2026-02-09 | Pitofsky Jason | Officer (SVP Controller) | Open-market sale | 53 | $785.72 | $41.6K | Form 4 |
| 2026-02-09 | Pitofsky Jason | Officer (SVP Controller) | Open-market sale | 1 | $784.66 | $785 | Form 4 |
| 2026-02-09 | Pitofsky Jason | Officer (SVP Controller) | Open-market sale | 144 | $783.23 | $112.8K | Form 4 |
| 2026-02-09 | Pitofsky Jason | Officer (SVP Controller) | Open-market sale | 37 | $782.67 | $29.0K | Form 4 |
| 2026-02-09 | Pitofsky Jason | Officer (SVP Controller) | Open-market sale | 26 | $781.37 | $20.3K | Form 4 |
| 2026-02-09 | Pitofsky Jason | Officer (SVP Controller) | Open-market sale | 75 | $780.06 | $58.5K | Form 4 |
| 2026-02-09 | Pitofsky Jason | Officer (SVP Controller) | Open-market sale | 205 | $779.56 | $159.8K | Form 4 |
| 2026-02-09 | Pitofsky Jason | Officer (SVP Controller) | Open-market sale | 563 | $778.35 | $438.2K | Form 4 |
| 2026-02-09 | Pitofsky Jason | Officer (SVP Controller) | Open-market sale | 391 | $777.51 | $304.0K | Form 4 |
| 2026-02-09 | Pitofsky Jason | Officer (SVP Controller) | Open-market sale | 521 | $776.43 | $404.5K | Form 4 |
| 2026-02-09 | Pitofsky Jason | Officer (SVP Controller) | Open-market sale | 20 | $775.95 | $15.5K | Form 4 |
| 2026-02-09 | Pitofsky Jason | Officer (SVP Controller) | Option exercise / conversion | 1,000 | $492.00 | $492.0K | Form 4 |
| 2026-01-07 | Bassler Bonnie L | Director | Option exercise / conversion (derivative) | 1,500 | — | $0 | Form 4 |
| 2026-01-07 | Bassler Bonnie L | Director | Open-market sale | 1,500 | $800.00 | $1.20M | Form 4 |
| 2026-01-07 | Bassler Bonnie L | Director | Option exercise / conversion | 1,500 | $374.12 | $561.2K | Form 4 |
| 2026-01-02 | Guarini Kathryn | Director | Grant / award / vesting (derivative) | 1,962 | — | $0 | Form 4 |
| 2026-01-02 | Guarini Kathryn | Director | Grant / award / vesting | 155 | — | $0 | Form 4 |
| 2026-01-02 | SING GEORGE L | Director | Grant / award / vesting (derivative) | 1,962 | — | $0 | Form 4 |
| 2026-01-02 | SING GEORGE L | Director | Grant / award / vesting | 155 | — | $0 | Form 4 |
| 2026-01-02 | Thompson Craig B. | Director | Grant / award / vesting (derivative) | 1,962 | — | $0 | Form 4 |
| 2026-01-02 | Thompson Craig B. | Director | Grant / award / vesting | 155 | — | $0 | Form 4 |
Ask the chat about REGN's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Regeneron Pharmaceuticals (REGN).
Last updated 2026-09-03 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.